Literature DB >> 8797985

Arterial angiography in high-kilovoltage technique with gadolinium as the contrast agent: first clinical experience.

F Fobbe1, F Wacker, S Wagner.   

Abstract

Iodine-containing contrast agents are currently used for angiography. However, due to the relatively low atomic number of iodine, imaging must be performed with a relatively low tube voltage. Gadolinium has been used for several years as a contrast agent in MRI with low adverse side effects. This substance has a higher atomic number as compared with iodine. We investigated whether the use of a gadolinium-containing contrast agent with a higher tube voltage reduces the radiation exposure in angiography, and how the image quality compares with the previous technique. A total of 15 patients were examined with either a survey angiography or a selective angiography. In all patients angiography was performed with an iodine-containing contrast agent with a tube voltage of 75 kV. Then gadolinium-containing contrast agent was administered immediately with a tube voltage of 110 kV. Radiation exposure and image quality were compared. On average, a dose reduction factor of 3.57 times was achieved by using 110 instead of 75 kV. However, the image quality was poorer in the majority of cases as compared with the images taken with iodine as a contrast agent and a tube voltage of 75 kV. The poorer image quality is caused by the relative low concentration (0.5 M) of the used gadolinium solution. A 1 M solution is currently tested for market approval and would probably solve this problem.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8797985     DOI: 10.1007/bf00181155

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  13 in total

1.  Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media.

Authors:  H Katayama; K Yamaguchi; T Kozuka; T Takashima; P Seez; K Matsuura
Journal:  Radiology       Date:  1990-06       Impact factor: 11.105

2.  Safety assessment of gadopentetate dimeglumine in U.S. clinical trials.

Authors:  H A Goldstein; F K Kashanian; R F Blumetti; W L Holyoak; F P Hugo; D M Blumenfield
Journal:  Radiology       Date:  1990-01       Impact factor: 11.105

3.  Case of anaphylaxis and four cases of allergic reaction following Gd-DTPA administration.

Authors:  O L Salonen
Journal:  J Comput Assist Tomogr       Date:  1990 Nov-Dec       Impact factor: 1.826

4.  [CT contrast administration of iodine, gadolinium and ytterbium. In-vitro studies and animal experiments].

Authors:  C Zwicker; M Langer; V Urich; R Felix
Journal:  Rofo       Date:  1993-03

5.  Gadopentetate dimeglumine as an alternative contrast material for use in angiography.

Authors:  Y Kinno; K Odagiri; K Andoh; Y Itoh; K Tarao
Journal:  AJR Am J Roentgenol       Date:  1993-06       Impact factor: 3.959

6.  Safety of MR contrast media.

Authors:  A Y Olukotun
Journal:  Radiology       Date:  1994-05       Impact factor: 11.105

7.  Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers.

Authors:  T Staks; G Schuhmann-Giampieri; T Frenzel; H J Weinmann; L Lange; J Platzek
Journal:  Invest Radiol       Date:  1994-07       Impact factor: 6.016

8.  An assessment of Gd-DTPA as a CT contrast agent in the renal tract.

Authors:  R J Gibson; C I Meanock; E P Torrie; T M Walker
Journal:  Clin Radiol       Date:  1993-04       Impact factor: 2.350

9.  Experimental and theoretical x-ray imaging performance comparison of iodine and lanthanide contrast agents.

Authors:  H N Cardinal; D W Holdsworth; M Drangova; B B Hobbs; A Fenster
Journal:  Med Phys       Date:  1993 Jan-Feb       Impact factor: 4.071

10.  Gd-DTPA: an alternative contrast medium for CT.

Authors:  A D Quinn; N J O'Hare; F J Wallis; G F Wilson
Journal:  J Comput Assist Tomogr       Date:  1994 Jul-Aug       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.